Global Scleroderma Therapy Market
Global Scleroderma Therapy Market

Scleroderma Therapy Comprehensive Study by Type (Immunosuppressors, Endothelin Receptor Antagonists, Phosphodiesterase 5 Inhibitors - PHA, Calcium Channel Blockers, Analgesic, Prostacyclin Analogues, Others), Type (Limited, Diffuse), Indication (Systemic, Localized), End User (Hospital, Clinics, Others) Players and Region - Global Market Outlook to 2026

Scleroderma Therapy Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Aug 2021 Edition 228 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Scleroderma Therapy Market?

Scleroderma is a chronic autoimmune disease affecting the skin, blood vessels, muscles, and internal organs. An aberrant immune response is usually the source of the illness. To treat this disease, immunosuppressive medications and, in rare circumstances, glucocorticoids are used.

The market study is being classified by Type (Immunosuppressors, Endothelin Receptor Antagonists, Phosphodiesterase 5 Inhibitors - PHA, Calcium Channel Blockers, Analgesic, Prostacyclin Analogues and Others) and major geographies with country level break-up.

Active Biotech AB (Sweden), Argentis Pharmaceuticals (United States), Allergan, Inc. (Ireland), BioLineRx, Ltd. (Israel), Bayer AG (Germany), Digna Biotech (Australia), F. Hoffmann-La Roche Ltd. (Switzerland), Angion Biomedica Corp. (United States), GlaxoSmithKline plc (United Kingdom) and Corbus Pharmaceuticals, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Daval International Ltd. (United Kingdom), Bristol-Myers Squibb Company (United States) and Dynavax Technologies Corporation (United States).

Top major competitors are investing in capacity, market shares, and recent events in the worldwide scleroderma therapeutics market. Because there are so many unmet medical requirements, the market for systemic scleroderma treatments is quite competitive. Large firms in the systemic scleroderma therapy industry are pursuing expansion methods such as mergers and acquisitions, partnerships, and strategic alliances. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Scleroderma Therapy market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Scleroderma Therapy market by Type, Application and Region.

On the basis of geography, the market of Scleroderma Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • The Need to Treat Scleroderma Condition for Improving the Patient Life is Driving the Market Growth
  • The surge in Demand for Scleroderma Therapy for Slowing Skin Thickening and Reducing the Effect on Internal Organs

Market Trend
  • The Ongoing Discoveries in the Pathogenesis of Scleroderma are Expected to Bring Revolution in the Traditional Therapy

Restraints
  • Side-Effect of Para-Aminobenzoic Acid (PABA), Colchicine, D-Penicillamine or Dimethyl Sulfoxide in Treatment may hamper the Scleroderma Therapy Market

Opportunities
  • Advancement in Medicine for more Effective Treatment may Provide Further Growth Avenues Will Propel the Scleroderma Therapy Market
  • The Development of First-In-Class Curatives that are Under Clinical Trials is Expected to Boost the Scleroderma Therapy Market.

Challenges
  • High Cost of Availing Scleroderma Therapy Challenges the Wide Adoption Among Lower Income Group Patients Will to hamper the Scleroderma Therapy Market


On 04 March 2021, Genentech announce the approval of Actemra by USFDA. A subcutaneous injection to decrease the speed of pulmonary function deterioration in adult patients with scleroderma, associated interstitial lung disease (SSc-ILD), a severe illness with few therapeutic alternatives. The FDA has authorized Actemra as the first biologic medication for the treatment of the illness. Actemra was previously given Priority Review status by the US Food and Drug Administration for the treatment of SSc-ILD.
“As per USFDA, Scleroderma patients require effective treatments, and the FDA supports drug firms' efforts to develop and execute the clinical trials required to offer therapeutic choices to scleroderma patients. Nintedanib is now a therapeutic option for individuals with scleroderma-related interstitial lung disease who are experiencing a gradual decrease in pulmonary function. Scleroderma is an uncommon illness that causes tissue to thicken and scar all throughout the body, including the lungs and other organs. ILD, or interstitial lung disease, is a disorder that affects the interstitium, a component of the lung's structure, and is one of the most frequent scleroderma disease presentations.”

Key Target Audience
Scleroderma Therapy Provider, Scleroderma Therapy Drug Manufactures, Scleroderma Therapy Distributors and Suppliers, Research and Development Institutes, Upstream and Downstream Buyers, Financial Institutes and Investors, Regulatory Bodies and Others

Frequently Asked Questions (FAQ):

1. Which factors would majorly drive the Scleroderma Therapy Market?
"The Need to Treat Scleroderma Condition for Improving the Patient Life is Driving the Market Growth " is seen as one of major growth factors of Scleroderma Therapy Market in years to come.

2. Can we have customized study for Scleroderma Therapy Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. Which region will lead the Global Scleroderma Therapy Market?
will lead the Scleroderma Therapy Market.
Report Objectives / Segmentation Covered
By Type
  • Immunosuppressors
  • Endothelin Receptor Antagonists
  • Phosphodiesterase 5 Inhibitors - PHA
  • Calcium Channel Blockers
  • Analgesic
  • Prostacyclin Analogues
  • Others
By Type
  • Limited
  • Diffuse

By Indication
  • Systemic
  • Localized

By End User
  • Hospital
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Need to Treat Scleroderma Condition for Improving the Patient Life is Driving the Market Growth
      • 3.2.2. The surge in Demand for Scleroderma Therapy for Slowing Skin Thickening and Reducing the Effect on Internal Organs
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Availing Scleroderma Therapy Challenges the Wide Adoption Among Lower Income Group Patients Will to hamper the Scleroderma Therapy Market
    • 3.4. Market Trends
      • 3.4.1. The Ongoing Discoveries in the Pathogenesis of Scleroderma are Expected to Bring Revolution in the Traditional Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Scleroderma Therapy, by Type, Type, Indication , End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Scleroderma Therapy (Value)
      • 5.2.1. Global Scleroderma Therapy by: Type (Value)
        • 5.2.1.1. Immunosuppressors
        • 5.2.1.2. Endothelin Receptor Antagonists
        • 5.2.1.3. Phosphodiesterase 5 Inhibitors - PHA
        • 5.2.1.4. Calcium Channel Blockers
        • 5.2.1.5. Analgesic
        • 5.2.1.6. Prostacyclin Analogues
        • 5.2.1.7. Others
      • 5.2.2. Global Scleroderma Therapy by: Type (Value)
        • 5.2.2.1. Limited
        • 5.2.2.2. Diffuse
      • 5.2.3. Global Scleroderma Therapy by: Type (Value)
        • 5.2.3.1. Immunosuppressors
        • 5.2.3.2. Endothelin Receptor Antagonists
        • 5.2.3.3. Phosphodiesterase 5 Inhibitors - PHA
        • 5.2.3.4. Calcium Channel Blockers
        • 5.2.3.5. Analgesic
        • 5.2.3.6. Prostacyclin Analogues
        • 5.2.3.7. Others
      • 5.2.4. Global Scleroderma Therapy by: Type (Value)
        • 5.2.4.1. Limited
        • 5.2.4.2. Diffuse
      • 5.2.5. Global Scleroderma Therapy by: End User (Value)
        • 5.2.5.1. Hospital
        • 5.2.5.2. Clinics
        • 5.2.5.3. Others
      • 5.2.6. Global Scleroderma Therapy Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Scleroderma Therapy (Price)
      • 5.3.1. Global Scleroderma Therapy by: Type (Price)
  • 6. Scleroderma Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Active Biotech AB (Sweden)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Argentis Pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Allergan, Inc. (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BioLineRx, Ltd. (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Digna Biotech (Australia)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Angion Biomedica Corp. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GlaxoSmithKline plc (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Corbus Pharmaceuticals, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Scleroderma Therapy Sale, by Type, Type, Indication , End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Scleroderma Therapy (Value)
      • 7.2.1. Global Scleroderma Therapy by: Type (Value)
        • 7.2.1.1. Immunosuppressors
        • 7.2.1.2. Endothelin Receptor Antagonists
        • 7.2.1.3. Phosphodiesterase 5 Inhibitors - PHA
        • 7.2.1.4. Calcium Channel Blockers
        • 7.2.1.5. Analgesic
        • 7.2.1.6. Prostacyclin Analogues
        • 7.2.1.7. Others
      • 7.2.2. Global Scleroderma Therapy by: Type (Value)
        • 7.2.2.1. Limited
        • 7.2.2.2. Diffuse
      • 7.2.3. Global Scleroderma Therapy by: Type (Value)
        • 7.2.3.1. Immunosuppressors
        • 7.2.3.2. Endothelin Receptor Antagonists
        • 7.2.3.3. Phosphodiesterase 5 Inhibitors - PHA
        • 7.2.3.4. Calcium Channel Blockers
        • 7.2.3.5. Analgesic
        • 7.2.3.6. Prostacyclin Analogues
        • 7.2.3.7. Others
      • 7.2.4. Global Scleroderma Therapy by: Type (Value)
        • 7.2.4.1. Limited
        • 7.2.4.2. Diffuse
      • 7.2.5. Global Scleroderma Therapy by: End User (Value)
        • 7.2.5.1. Hospital
        • 7.2.5.2. Clinics
        • 7.2.5.3. Others
      • 7.2.6. Global Scleroderma Therapy Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Scleroderma Therapy (Price)
      • 7.3.1. Global Scleroderma Therapy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Scleroderma Therapy: by Type(USD Million)
  • Table 2. Scleroderma Therapy Immunosuppressors , by Region USD Million (2015-2020)
  • Table 3. Scleroderma Therapy Endothelin Receptor Antagonists , by Region USD Million (2015-2020)
  • Table 4. Scleroderma Therapy Phosphodiesterase 5 Inhibitors - PHA , by Region USD Million (2015-2020)
  • Table 5. Scleroderma Therapy Calcium Channel Blockers , by Region USD Million (2015-2020)
  • Table 6. Scleroderma Therapy Analgesic , by Region USD Million (2015-2020)
  • Table 7. Scleroderma Therapy Prostacyclin Analogues , by Region USD Million (2015-2020)
  • Table 8. Scleroderma Therapy Others , by Region USD Million (2015-2020)
  • Table 9. Scleroderma Therapy: by Type(USD Million)
  • Table 10. Scleroderma Therapy Limited , by Region USD Million (2015-2020)
  • Table 11. Scleroderma Therapy Diffuse , by Region USD Million (2015-2020)
  • Table 12. Scleroderma Therapy: by Type(USD Million)
  • Table 13. Scleroderma Therapy Immunosuppressors , by Region USD Million (2015-2020)
  • Table 14. Scleroderma Therapy Endothelin Receptor Antagonists , by Region USD Million (2015-2020)
  • Table 15. Scleroderma Therapy Phosphodiesterase 5 Inhibitors - PHA , by Region USD Million (2015-2020)
  • Table 16. Scleroderma Therapy Calcium Channel Blockers , by Region USD Million (2015-2020)
  • Table 17. Scleroderma Therapy Analgesic , by Region USD Million (2015-2020)
  • Table 18. Scleroderma Therapy Prostacyclin Analogues , by Region USD Million (2015-2020)
  • Table 19. Scleroderma Therapy Others , by Region USD Million (2015-2020)
  • Table 20. Scleroderma Therapy: by Type(USD Million)
  • Table 21. Scleroderma Therapy Limited , by Region USD Million (2015-2020)
  • Table 22. Scleroderma Therapy Diffuse , by Region USD Million (2015-2020)
  • Table 23. Scleroderma Therapy: by End User(USD Million)
  • Table 24. Scleroderma Therapy Hospital , by Region USD Million (2015-2020)
  • Table 25. Scleroderma Therapy Clinics , by Region USD Million (2015-2020)
  • Table 26. Scleroderma Therapy Others , by Region USD Million (2015-2020)
  • Table 27. South America Scleroderma Therapy, by Country USD Million (2015-2020)
  • Table 28. South America Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 29. South America Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 30. South America Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 31. South America Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 32. Brazil Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 33. Brazil Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 34. Brazil Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 35. Brazil Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 36. Argentina Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 37. Argentina Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 38. Argentina Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 39. Argentina Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 40. Rest of South America Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 41. Rest of South America Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 42. Rest of South America Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 43. Rest of South America Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 44. Asia Pacific Scleroderma Therapy, by Country USD Million (2015-2020)
  • Table 45. Asia Pacific Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 46. Asia Pacific Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 47. Asia Pacific Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 48. Asia Pacific Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 49. China Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 50. China Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 51. China Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 52. China Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 53. Japan Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 54. Japan Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 55. Japan Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 56. Japan Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 57. India Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 58. India Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 59. India Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 60. India Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 61. South Korea Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 62. South Korea Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 63. South Korea Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 64. South Korea Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 65. Taiwan Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 66. Taiwan Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 67. Taiwan Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 68. Taiwan Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 69. Australia Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 70. Australia Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 71. Australia Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 72. Australia Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 73. Rest of Asia-Pacific Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 74. Rest of Asia-Pacific Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 75. Rest of Asia-Pacific Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 76. Rest of Asia-Pacific Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 77. Europe Scleroderma Therapy, by Country USD Million (2015-2020)
  • Table 78. Europe Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 79. Europe Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 80. Europe Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 81. Europe Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 82. Germany Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 83. Germany Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 84. Germany Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 85. Germany Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 86. France Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 87. France Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 88. France Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 89. France Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 90. Italy Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 91. Italy Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 92. Italy Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 93. Italy Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 94. United Kingdom Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 95. United Kingdom Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 96. United Kingdom Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 97. United Kingdom Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 98. Netherlands Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 99. Netherlands Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 100. Netherlands Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 101. Netherlands Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 102. Rest of Europe Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 103. Rest of Europe Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 104. Rest of Europe Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 105. Rest of Europe Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 106. MEA Scleroderma Therapy, by Country USD Million (2015-2020)
  • Table 107. MEA Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 108. MEA Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 109. MEA Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 110. MEA Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 111. Middle East Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 112. Middle East Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 113. Middle East Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 114. Middle East Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 115. Africa Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 116. Africa Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 117. Africa Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 118. Africa Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 119. North America Scleroderma Therapy, by Country USD Million (2015-2020)
  • Table 120. North America Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 121. North America Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 122. North America Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 123. North America Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 124. United States Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 125. United States Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 126. United States Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 127. United States Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 128. Canada Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 129. Canada Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 130. Canada Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 131. Canada Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 132. Mexico Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 133. Mexico Scleroderma Therapy, by Type USD Million (2015-2020)
  • Table 134. Mexico Scleroderma Therapy, by Indication USD Million (2015-2020)
  • Table 135. Mexico Scleroderma Therapy, by End User USD Million (2015-2020)
  • Table 136. Scleroderma Therapy: by Type(USD/Units)
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Scleroderma Therapy: by Type(USD Million)
  • Table 148. Scleroderma Therapy Immunosuppressors , by Region USD Million (2021-2026)
  • Table 149. Scleroderma Therapy Endothelin Receptor Antagonists , by Region USD Million (2021-2026)
  • Table 150. Scleroderma Therapy Phosphodiesterase 5 Inhibitors - PHA , by Region USD Million (2021-2026)
  • Table 151. Scleroderma Therapy Calcium Channel Blockers , by Region USD Million (2021-2026)
  • Table 152. Scleroderma Therapy Analgesic , by Region USD Million (2021-2026)
  • Table 153. Scleroderma Therapy Prostacyclin Analogues , by Region USD Million (2021-2026)
  • Table 154. Scleroderma Therapy Others , by Region USD Million (2021-2026)
  • Table 155. Scleroderma Therapy: by Type(USD Million)
  • Table 156. Scleroderma Therapy Limited , by Region USD Million (2021-2026)
  • Table 157. Scleroderma Therapy Diffuse , by Region USD Million (2021-2026)
  • Table 158. Scleroderma Therapy: by Type(USD Million)
  • Table 159. Scleroderma Therapy Immunosuppressors , by Region USD Million (2021-2026)
  • Table 160. Scleroderma Therapy Endothelin Receptor Antagonists , by Region USD Million (2021-2026)
  • Table 161. Scleroderma Therapy Phosphodiesterase 5 Inhibitors - PHA , by Region USD Million (2021-2026)
  • Table 162. Scleroderma Therapy Calcium Channel Blockers , by Region USD Million (2021-2026)
  • Table 163. Scleroderma Therapy Analgesic , by Region USD Million (2021-2026)
  • Table 164. Scleroderma Therapy Prostacyclin Analogues , by Region USD Million (2021-2026)
  • Table 165. Scleroderma Therapy Others , by Region USD Million (2021-2026)
  • Table 166. Scleroderma Therapy: by Type(USD Million)
  • Table 167. Scleroderma Therapy Limited , by Region USD Million (2021-2026)
  • Table 168. Scleroderma Therapy Diffuse , by Region USD Million (2021-2026)
  • Table 169. Scleroderma Therapy: by End User(USD Million)
  • Table 170. Scleroderma Therapy Hospital , by Region USD Million (2021-2026)
  • Table 171. Scleroderma Therapy Clinics , by Region USD Million (2021-2026)
  • Table 172. Scleroderma Therapy Others , by Region USD Million (2021-2026)
  • Table 173. South America Scleroderma Therapy, by Country USD Million (2021-2026)
  • Table 174. South America Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 175. South America Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 176. South America Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 177. South America Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 178. Brazil Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 179. Brazil Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 180. Brazil Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 181. Brazil Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 182. Argentina Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 183. Argentina Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 184. Argentina Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 185. Argentina Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 186. Rest of South America Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 187. Rest of South America Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 188. Rest of South America Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 189. Rest of South America Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 190. Asia Pacific Scleroderma Therapy, by Country USD Million (2021-2026)
  • Table 191. Asia Pacific Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 192. Asia Pacific Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 193. Asia Pacific Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 194. Asia Pacific Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 195. China Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 196. China Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 197. China Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 198. China Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 199. Japan Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 200. Japan Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 201. Japan Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 202. Japan Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 203. India Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 204. India Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 205. India Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 206. India Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 207. South Korea Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 208. South Korea Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 209. South Korea Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 210. South Korea Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 211. Taiwan Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 212. Taiwan Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 213. Taiwan Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 214. Taiwan Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 215. Australia Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 216. Australia Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 217. Australia Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 218. Australia Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 219. Rest of Asia-Pacific Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 220. Rest of Asia-Pacific Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 221. Rest of Asia-Pacific Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 222. Rest of Asia-Pacific Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 223. Europe Scleroderma Therapy, by Country USD Million (2021-2026)
  • Table 224. Europe Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 225. Europe Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 226. Europe Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 227. Europe Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 228. Germany Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 229. Germany Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 230. Germany Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 231. Germany Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 232. France Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 233. France Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 234. France Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 235. France Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 236. Italy Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 237. Italy Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 238. Italy Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 239. Italy Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 240. United Kingdom Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 241. United Kingdom Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 242. United Kingdom Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 243. United Kingdom Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 244. Netherlands Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 245. Netherlands Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 246. Netherlands Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 247. Netherlands Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 248. Rest of Europe Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 249. Rest of Europe Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 250. Rest of Europe Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 251. Rest of Europe Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 252. MEA Scleroderma Therapy, by Country USD Million (2021-2026)
  • Table 253. MEA Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 254. MEA Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 255. MEA Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 256. MEA Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 257. Middle East Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 258. Middle East Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 259. Middle East Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 260. Middle East Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 261. Africa Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 262. Africa Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 263. Africa Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 264. Africa Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 265. North America Scleroderma Therapy, by Country USD Million (2021-2026)
  • Table 266. North America Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 267. North America Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 268. North America Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 269. North America Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 270. United States Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 271. United States Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 272. United States Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 273. United States Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 274. Canada Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 275. Canada Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 276. Canada Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 277. Canada Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 278. Mexico Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 279. Mexico Scleroderma Therapy, by Type USD Million (2021-2026)
  • Table 280. Mexico Scleroderma Therapy, by Indication USD Million (2021-2026)
  • Table 281. Mexico Scleroderma Therapy, by End User USD Million (2021-2026)
  • Table 282. Scleroderma Therapy: by Type(USD/Units)
  • Table 283. Research Programs/Design for This Report
  • Table 284. Key Data Information from Secondary Sources
  • Table 285. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Scleroderma Therapy: by Type USD Million (2015-2020)
  • Figure 5. Global Scleroderma Therapy: by Type USD Million (2015-2020)
  • Figure 6. Global Scleroderma Therapy: by Type USD Million (2015-2020)
  • Figure 7. Global Scleroderma Therapy: by Type USD Million (2015-2020)
  • Figure 8. Global Scleroderma Therapy: by End User USD Million (2015-2020)
  • Figure 9. South America Scleroderma Therapy Share (%), by Country
  • Figure 10. Asia Pacific Scleroderma Therapy Share (%), by Country
  • Figure 11. Europe Scleroderma Therapy Share (%), by Country
  • Figure 12. MEA Scleroderma Therapy Share (%), by Country
  • Figure 13. North America Scleroderma Therapy Share (%), by Country
  • Figure 14. Global Scleroderma Therapy: by Type USD/Units (2015-2020)
  • Figure 15. Global Scleroderma Therapy share by Players 2020 (%)
  • Figure 16. Global Scleroderma Therapy share by Players (Top 3) 2020(%)
  • Figure 17. Global Scleroderma Therapy share by Players (Top 5) 2020(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Active Biotech AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 20. Active Biotech AB (Sweden) Revenue: by Geography 2020
  • Figure 21. Argentis Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 22. Argentis Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 23. Allergan, Inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 24. Allergan, Inc. (Ireland) Revenue: by Geography 2020
  • Figure 25. BioLineRx, Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 26. BioLineRx, Ltd. (Israel) Revenue: by Geography 2020
  • Figure 27. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 29. Digna Biotech (Australia) Revenue, Net Income and Gross profit
  • Figure 30. Digna Biotech (Australia) Revenue: by Geography 2020
  • Figure 31. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 33. Angion Biomedica Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Angion Biomedica Corp. (United States) Revenue: by Geography 2020
  • Figure 35. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 37. Corbus Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Corbus Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Global Scleroderma Therapy: by Type USD Million (2021-2026)
  • Figure 40. Global Scleroderma Therapy: by Type USD Million (2021-2026)
  • Figure 41. Global Scleroderma Therapy: by Type USD Million (2021-2026)
  • Figure 42. Global Scleroderma Therapy: by Type USD Million (2021-2026)
  • Figure 43. Global Scleroderma Therapy: by End User USD Million (2021-2026)
  • Figure 44. South America Scleroderma Therapy Share (%), by Country
  • Figure 45. Asia Pacific Scleroderma Therapy Share (%), by Country
  • Figure 46. Europe Scleroderma Therapy Share (%), by Country
  • Figure 47. MEA Scleroderma Therapy Share (%), by Country
  • Figure 48. North America Scleroderma Therapy Share (%), by Country
  • Figure 49. Global Scleroderma Therapy: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Active Biotech AB (Sweden)
  • Argentis Pharmaceuticals (United States)
  • Allergan, Inc. (Ireland)
  • BioLineRx, Ltd. (Israel)
  • Bayer AG (Germany)
  • Digna Biotech (Australia)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Angion Biomedica Corp. (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Corbus Pharmaceuticals, Inc. (United States)
Additional players considered in the study are as follows:
Daval International Ltd. (United Kingdom) , Bristol-Myers Squibb Company (United States) , Dynavax Technologies Corporation (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation